Batu Biologics Publishes Preclinical Data for ValloVax™

Batu Biologics Publishes Preclinical Data for ValloVax™

Company authors peer-reviewed publication about lung cancer immune therapy targeting the tumor endothelium

Batu Biologics announced today publication in the Journal of Translational Medicine of the rationale and preclinical data for Batu’s flagship immunotherapeutic product, ValloVax™.

Read the full article at businesswire.com

0